Full-Time
Updated on 9/3/2026
Value-based oncology care navigation platform
$246.5k - $290k/yr
Remote in USA
Remote
The role may also be performed in a hybrid setting from Nashville or New York City offices.
See people who can refer or advise you
Thyme Care enables value-based cancer care by partnering with health plans, employers, and risk-bearing providers to reduce total cancer costs while improving outcomes. It combines a dedicated, technology-enabled Care Team with Thyme Box, a data analytics platform that integrates with clinical workflows to identify at-risk patients, coordinate care, and provide 24/7 virtual support. Patients have a single point of contact to manage appointments, transportation, and understanding their diagnosis, and Thyme Care only earns revenue from savings it generates for partners. The company differentiates itself through deep oncology expertise, seamless workflow integration, and a patient-centered care model, with a goal to lower costs and grow the Thyme Companies portfolio to address broader aspects of the cancer journey.
Company Size
501-1,000
Company Stage
Series E
Total Funding
$397M
Headquarters
Nashville, Tennessee
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Remote Work Options
Company Equity
Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion. Sep 4, 2026 - 03:17 L to R: Thyme Care Co-founder and Chief Medical Officer Bobby Green,; Thyme Companies Executive Chairman Robin Shah; Thyme Care CEO Brad Diephuis Courtesy: Thyme Care Despite recent advancements in oncology, the branch of medicine focused on the study, prevention, diagnosis and treatment of cancer, it remains one of the most expensive, arduous and overwhelming diagnoses to navigate. Thyme Care, launched in 2020 and ranked No. 18 on the 2026 CNBC Disruptor 50 list, has focused on improving the fragmentation and disconnections in cancer care through its virtual navigation platform for patients. To extend its efforts, Thyme Care has raised $125 million from investors in a Series E funding round at a valuation of more than $2 billion, it announced on Wednesday. The deal, led by Morgan Health with participation from strategic healthcare investors Humana and CVS Health Ventures, roughly doubled its valuation from a Series D less than a year ago. Other investors include AlleyCorp, HealthQuest Capital, and a16z Bio + Health. Thyme Care is now forming a new parent company focused on building additional businesses that will address some of those disconnections in how cancer care is delivered, accessed and paid for. Robin Shah, who co-founded Thyme Care alongside Bobby Green, will serve as the executive chairman of the new parent entity, which will be called Thyme Companies. Shah said that the timing was right to take this next step in the journey to improve the cancer care system. "When Bobby and I started this business six years ago, we had this vision that we needed to go after all the white spaces that were being constantly overlooked in oncology," said Shah, adding that Thyme Care aimed to address "the care in between," or the things and questions that come up between appointments and visits. Thyme Care has grown into that role. The company's services are available to more than 10.5 million people across all 50 U.S. states, and it manages more than $7 billion in oncology spend. Revenue surpassed $125 million last year, five times more than the previous year. More coverage of the 2026 CNBC Disruptor 50. Shah stepped down as CEO of Thyme Care in July, appointing Brad Diephuis, who previously served as the company's president and chief operating officer, as his replacement. Shah said that Diephuis had been a significant driver of Thyme Care's business, and this move now allows him to focus on Thyme Companies, "the platform for us to build out other initiatives or full companies that are focused on these [oncology] problems," he said. One of the first focuses under the new corporate structure will be addressing cancer drug affordability, Shah said, with a goal of accelerating the adoption of lower-cost biosimilars, which are clinically equivalent drugs akin to generic drugs. To date, cancer-focused biosimilars have not delivered as much cost savings to patients as promised, according to Shah, and Thyme Companies will work with health plans and providers to find meaningful savings. The other initial focus for Thyme Companies will be around improving access and navigation within the clinical trial space, where Shah said enrollment challenges are limiting patient access to beneficial trials and slowing drug development. The first of these businesses is expected to launch later this year. Shah said that Thyme Care is now profitable, generating positive free cash flow, and "has a large balance sheet to make investments that we wouldn't have been able to three years ago." He said acquisitions of other businesses that could help solve some of these oncology challenges, as well as recruitment of additional talent, are also on the table. Shah said the company does not have any "near-term viewpoint" on an IPO, but said it will continue to evaluate public and private investment opportunities that "will allow us to move faster, because we think this is a problem that impacts everyone in the country, let alone the world." "We have a team that is focused on being together for the long term to solve problems in healthcare with a hyperfocus on oncology," Shah said.
Thyme Care raises $125M, launches new oncology parent entity. Thyme Care's Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. Thyme Care, an oncology company, announced Wednesday that it secured more than $125 million in Series E financing, bringing its valuation to over $2 billion. The company also announced the creation of a new parent company that seeks to build a portfolio of businesses tackling different parts of the oncology space. Nashville, Tennessee-based Thyme Care, founded in 2020, partners with health plans, employers and risk-bearing providers to support patients battling cancer. It offers care navigation services, technology and data insights and therapeutic interventions. The company helps patients understand their diagnosis, find a cancer doctor and receive clinical care between appointments. Patients also gain access to a team of providers, nurses and resource specialists. Its services are available to 10.5 million people across all 50 states. The Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. presented by What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes. "People living with cancer have traditionally been left to coordinate care themselves and pay more along the way. Thyme Care is changing that experience and making it possible to improve cancer care while lowering costs," said Dan Mendelson, CEO of Morgan Health, in a statement. "We're continuing to invest in Thyme Care because we're confident they can continue to deliver value to patients and payers - as they make the next wave of cancer care innovation easier to access and navigate." Thyme Care also announced the creation of Thyme Companies, a new parent entity that will build a portfolio of independent oncology businesses. These businesses aim to accelerate the adoption of lower-cost biosimilars and increase clinical trial enrollment. The first business is anticipated to launch later this year. Thyme Care Co-Founder Robin Shah will become executive chairman of Thyme Companies, leading strategy and new business development. Thyme Care will continue under CEO Dr. Brad Diephuis, with Co-Founder Dr. Bobby Green as president and chief medical officer. The funding will drive Thyme Care's value-based care business while supporting the growth of Thyme Companies, Diephuis told MedCity News. We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey. "Our top priority is delivering for the members and partners we already serve, maintaining the high-value experience our members count on, and continuing to expand, including further into the commercial market," Diephuis said. "Our core business is profitable and growing, and this capital lets us keep scaling it while pushing into more parts of the oncology journey than we touch today." Other companies that provide cancer care support include OncoveryCare and Maia Oncology.
Thyme Care raises $125 million, pushing cancer care startup's valuation above $2 billion. Published Wed, Sep 2 202611:15 AM EDT Listen 4min Key Points * Thyme Care has raised $125 million from investors in a fundraising round that doubled its valuation to above $2 billion. * The cancer care startup focuses on filling gaps in patient treatment through a virtual navigation platform, and is now creating a new parent company to focus on challenges from drug affordability to clinical trial access. * Launched in 2020, the company ranked No. 18 on the 2026 CNBC Disruptor 50 list. L to R: Thyme Care Co-founder and Chief Medical Officer Bobby Green,; Thyme Companies Executive Chairman Robin Shah; Thyme Care CEO Brad Diephuis Despite recent advancements in oncology, the branch of medicine focused on the study, prevention, diagnosis and treatment of cancer, it remains one of the most expensive, arduous and overwhelming diagnoses to navigate. Thyme Care, launched in 2020 and ranked No. 18 on the 2026 CNBC Disruptor 50 list, has focused on improving the fragmentation and disconnections in cancer care through its virtual navigation platform for patients. To extend its efforts, Thyme Care has raised $125 million from investors in a Series E funding round at a valuation of more than $2 billion, it announced on Wednesday. The deal, led by Morgan Health with participation from strategic healthcare investors Humana and CVS Health Ventures, roughly doubled its valuation from a Series D less than a year ago. Other investors include AlleyCorp, HealthQuest Capital, and a16z Bio + Health. Thyme Care is now forming a new parent company focused on building additional businesses that will address some of those disconnections in how cancer care is delivered, accessed and paid for. Robin Shah, who co-founded Thyme Care alongside Bobby Green, will serve as the executive chairman of the new parent entity, which will be called Thyme Companies. Shah said that the timing was right to take this next step in the journey to improve the cancer care system. "When Bobby and I started this business six years ago, we had this vision that we needed to go after all the white spaces that were being constantly overlooked in oncology," said Shah, adding that Thyme Care aimed to address "the care in between," or the things and questions that come up between appointments and visits. Thyme Care has grow into that role. The company's services are available to more than 10.5 million people across all 50 U.S. states, and it manages more than $7 billion in oncology spend. Revenue surpassed $125 million last year, five times more than the previous year. Shah stepped down as CEO of Thyme Care in July, appointing Brad Diephuis, who previously served as the company's president and chief operating officer, as his replacement. Shah said that Diephuis had been a significant driver of Thyme Care's business, and this move now allows him to focus on Thyme Companies, "the platform for us to build out other initiatives or full companies that are focused on these [oncology] problems," he said. One of the first focuses under the new corporate structure will be addressing cancer drug affordability, Shah said, with a goal of accelerating the adoption of lower-cost biosimilars, which are clinically equivalent drugs akin to generic drugs. To date, cancer-focused biosimilars have not delivered as much cost savings to patients as promised, according to Shah, and Thyme Companies will work with health plans and providers to find meaningful savings. The other initial focus for Thyme Companies will be around improving access and navigation within the clinical trial space, where Shah said enrollment challenges are limiting patient access to beneficial trials and slowing drug development. The first of these businesses is expected to launch later this year. Shah said that Thyme Care is now profitable, generating positive free cash flow, and "has a large balance sheet to make investments that we wouldn't have been able to three years ago." He said acquisitions of other businesses that could help solve some of these oncology challenges, as well as recruitment of additional talent, are also on the table. Shah said the company does not have any "near-term viewpoint" on an IPO, but said it will continue to evaluate public and private investment opportunities that "will allow us to move faster, because we think this is a problem that impacts everyone in the country, let alone the world." "We have a team that is focused on being together for the long term to solve problems in healthcare with a hyperfocus on oncology," Shah said.
Thyme Care, a Nashville-based oncology company, has closed a Series E funding round of more than $125 million at a valuation exceeding $2 billion. Morgan Health led the round, with participation from CVS Health Ventures, Humana, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, and a16z Bio + Health. The company now serves over 10.5 million people across all 50 US states and manages more than $7 billion in oncology spend. Thyme Care reports it is profitable with positive free cash flow whilst delivering validated reductions of 5 to 10 per cent in total cost of care. Alongside the funding, Thyme Care is establishing Thyme Companies, a parent entity that will build a portfolio of independent oncology businesses addressing care barriers. Co-founder Robin Shah will serve as executive chairman of the new entity.
Oncology company Thyme Care raises $125M, backed by morgan health, humana and CVS health ventures. September 2, 2026 Thyme Care landed a series E financing round of more than $125 million backed by strategic payers and providers as it aims to expand beyond cancer care navigation.